Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

ARCHCARE SENIOR LIFE PACE PROGRAM PARTNERS WITH INTUS CARE TO DELIVER A DATA DRIVEN APPROACH TO EXCEPTIONAL ELDER CARE

Intus Care

ArchCare, the Archdiocese of New York’s healthcare system that every day cares for more than 10,000 seniors, the poor, and persons with special needs, in partnership with Intus Care, developer of innovative predictive software and services designed for geriatric health, has recently implemented data-driven software that more accurately identifies high-risk elders in its ArchCare Senior Life, Program of All-inclusive Care for the Elderly (PACE). ArchCare will utilize Intus Care’s Integrated Care Services and its software analytics platform to allow ArchCare caregivers to mount an immediate, aggressive response. ArchCare Senior Life, Program of All-inclusive Care for the Elderly (PACE), is a comprehensive and innovative model of care for people 55 years of age and older who qualify for nursing-home-level care. PACE is a government Medicare and Medicaid program designed to support older Americans who wish to remain living in their homes by providing comprehensive medical and social services, including medical management, transportation, and assistance with daily activities. ArchCare leverages advanced technologies to serve its population of residents and participants across its system of nursing homes and PACE centers. ArchCare will utilize Intus Care’s Integrated Care Services and its software analytics platform to optimize the care provided to adults enrolled in ArchCare Senior Life, which serves elders in Manhattan, The Bronx, Staten Island, and Westchester. Intus Care is a developer of innovative predictive software and services designed for geriatric health. “With this new technology, we can pinpoint who is at risk for a decline, fall or other adverse event, and focus care where it’s needed immediately," said Dr. Walid Michelen, Senior Vice President, Clinical Planning & Innovation and Chief Medical Officer, ArchCare. “Intus Care’s Integrated Care Services tool helps us ensure that ArchCare’s PACE participants are receiving the most effective care and support to enhance their quality of life." By utilizing comprehensive, duals-specific algorithms, Intus Care identifies participants at high risk for hospitalizations and chronic disease onset - allowing ArchCare’s PACE program to optimize care planning. Intus Care has a team of PACE experts committed to helping geriatric care programs grow and improve their operations. Working collaboratively with leadership teams and staff, the ICS process executes project work plans, creates a data-driven culture to improve clinical outcomes, ensures CMS compliance, manages utilization, and optimizes quality. Over the last year, Intus Care has increased its presence in NYC with an office on East 78th Street, a growing employee base in the area, and the relocation of several leadership team members. “ArchCare is a forward-thinking PACE program in Manhattan, New York, with a fantastic team, providing hundreds of participants high-quality, individualized care as they age in place,” said Laura Ferrara, Chief Strategy Officer at Intus Care. “We are proud to work with ArchCare, empowering their team through data-driven decisions, optimizing care outcomes, operational practices, and compliance alignment across the program.” About ArchCare ArchCare is the Continuing Care Community of the Archdiocese of New York, and one of the nation’s largest and most dynamic Catholic healthcare systems. ArchCare provides quality care to thousands of people of all faiths through its home and community-based and residential care programs, including health plans and nursing home alternatives, adult day care, long-term skilled nursing care, short-term rehabilitation, home care, assisted living, hospice, an acute care specialty hospital and services for people with Huntington’s disease, HIV/AIDS, developmental disabilities, and other specialized care needs. About Intus Care Intus Care leverages analytics and data-driven services to improve care for the healthcare system’s most socially vulnerable and clinically complex patients. By integrating disparate data sources, highlighting patient risk, and implementing innovative processes, Intus Care empowers managed care organizations, including PACE programs and Special Needs Plans (SNPs), to make informed decisions and drive outcomes. Contact Details SVM Public Relations Jordan Bouclin & Alison Matthiessen +1 401-490-9700 intuscare@svmpr.com ArchCare Sarah McAllister +1 212-576-2700 Goodman.ArchCare@goodmanmedia.com Company Website https://www.intuscare.com/

June 06, 2023 10:00 AM Eastern Daylight Time

LiveSpo represents Vietnam, announces world's first spore probiotics in nasal spray form at the BIO International Convention

LiveSpo

HANOI, VIETNAM - Media OutReach - 6 June 2023 - LiveSpo is the first representative from Vietnam to participate in the BIO International Convention, an exhibition showcasing breakthrough biotechnology solutions, held in Boston, USA. This demonstrates remarkable development of the Vietnamese pharmaceutical sector in the realm of biotechnology. The BIO International Convention, held annually in the United States in June, attracts approximately 14,000 attendees from 65 countries. It serves as a platform for biopharmaceutical companies, investors, and government leaders to exchange ideas, present research findings, and explore partnership opportunities in the field. This year, the convention takes place from June 5 to 8 at the Boston Convention & Exhibition Center in Massachusetts, USA. Among the 1,200 booths, LiveSpo Pharma proudly represents Vietnam as the sole participant, introducing "Made in Vietnam" spore probiotics technology for respiratory disease treatment. Dr. Nguyen Hoa Anh, R&D Director and Chairman of LiveSpo Pharma, will present LiveSpo's breakthrough spore probiotics technology at the BIO International Convention 2023. This technology features liquid-form, multi-strain, high-concentration probiotics, including the flagship product LiveSpo NAVAX, a pre-active SPL spore probiotic delivered in the form of nasal spray. After undergoing rigorous clinical trials aligned with US standards, LiveSpo NAVAX has emerged as the world's first spore probiotic nasal spray. Its significant impact on reducing treatment duration for acute respiratory infections in children has been proven. LiveSpo NAVAX demonstrates an exceptional ability to reduce the load of Respiratory Syncytial Virus (RSV) by 600-fold and influenza virus by 900-fold. The safety and remarkable efficacy of this product have been published in the esteemed Scientific Reports journal (Nature), and the article ranked among the top 100 most downloaded in 2022. (Reference: https://www.nature.com/articles/s41598-022-16136-z ) The presence of LiveSpo NAVAX at the BIO International Convention 2023 signifies the leapfrog development of Vietnamese science in the probiotics industry, particularly spore probiotics technology, which has gained traction as a healthcare trend worldwide. Moreover, it offers an opportunity to promote breakthrough "Made in Vietnam" technology globally, providing safe and sustainable treatment options to more patients, particularly children. LiveSpo NAVAX addresses the treatment needs of 80 percent of children under two years old infected with RSV, a condition currently lacking a cure. It also presents a path towards "A Future Without Antibiotics", mitigating the persistent global health concern of antibiotic overuse. During the BIO International Convention, LiveSpo Pharma will engage in B2B meetings with partners from various countries, including Turkey, the UK, Canada, Spain, Australia, Brazil, India, France, and others. Discussions will revolve around the potential and practical applications of breakthrough spore probiotics, as well as opportunities for exclusive distribution of LiveSpo products in international markets. The Vietnamese representative will also host a booth and participate in thematic seminars to explore and remain updated on scientific and technological advancements in developed countries. Dang Quoc Hung, CEO/Managing Director of LiveSpo, expressed excitement about the opportunity to join the BIO International Convention 2023, stating, "Participating in the world's leading exhibition of breakthrough biotechnology solutions testifies to LiveSpo's readiness and competitiveness in the global pharmaceutical market. This milestone serves as a stepping stone towards realizing our vision of introducing Vietnamese biotechnology and LiveSpo spore probiotics to more countries, showcasing Vietnam's capacity to produce products with high knowledge content." About BIO: BIO International Convention, which is organized by BIO, is the world’s largest gathering of leading investors and partners in the biotechnology industry.Founded in 1993, BIO is the world’s largest advocacy association representing member companies, research institutions, state biotechnology groups, and related organizations across the US and in over 30 countries. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial, and environmental biotechnology products. About LiveSpo Pharma: LiveSpo is an R&D, manufacturing, and distribution brand of Spobiotics (probiotics in spore form) for digestive and respiratory health, leading in breakthrough technology, rapid effectiveness, and convenience, aiming for "A Future Without Antibiotics".LiveSpo has applied spore probiotics technology to develop breakthrough products in liquid form, multi-strain, and high concentration, pioneering in protecting and improving the community's health in a comprehensive, natural and effective way.LiveSpo's outstanding achievements:- Attended the 13th International Scientific Conference on Probiotics, Prebiotics, Gut Microbiota and Health (IPC 2019) in Prague, Czech Republic.- The only Vietnamese representative on probiotics to attend the International Microbiology Conference 2022 (ASM 2022).- LiveSpo's clinical trial research is published in the Scientific Reports journal (the Nature): LiveSpo NAVAX supports the treatment of acute respiratory infections in children infected with RSV Effects of nasal-spraying LiveSpo NAVAX in treatment of acute respiratory infections in children Effects of LiveSpo CLAUSY and LiveSpo DIA 30 in treatment of persistent diarrhea in children Effects of LiveSpo X-SECRET in supporting treatment of sexually transmitted diseases Email: huong.md@livespo.com Contact Details (Ms) Mai Dieu Huong huong.md@livespo.com Company Website https://livespo.com/en/

June 06, 2023 09:31 AM Eastern Daylight Time

Image

Algernon Pharmaceuticals plans Phase 2 stroke and TBI study after successful DMT single dose study

Algernon Pharmaceuticals Inc.

Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to provide an update on subsidiary Algernon NeuroScience successfully completing the highest planned single dose of its escalating Phase 1 clinical study of an intravenous formulation of AP-188 or DMT. The company is looking to investigate DMT for treatment of stroke and traumatic brain injury. Moreau telling Proactive the committee tasked with reviewing the program has confirmed that there were no safety or tolerability issues with the highest dose, which was able to maintain plasma DMT concentrations at targeted levels and which was below the established psychedelic dose. The company says the second part of the study will include dosing subjects for 6 hours with repeated administrations over a two-week period which can be used in its first Phase 2 study for stroke and TBI. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

June 05, 2023 01:43 PM Eastern Daylight Time

Video

News Release

BioHarvest Sciences 1Q financials show continued growth with a 209% year-over-year increase

BioHarvest Sciences Inc.

BioHarvest Sciences CEO Ilan Sobel joined Steve Darling from Proactive to share news the company has released first-quarter 2023 financial numbers that show big gains over 2022. The company saw VINIA revenues growing 209% compared to 1Q 2022, reaching $2.2 million. Sobel also shared with Proactive the company saw gross margins increase to 37%, from 26% a year earlier. The company is sticking with its guidance of year-over-year revenue growing three times to over $17 million. BioHarvest is looking to be cash flow break-even in 4Q 2023. Contact Details Proactive Investors Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

June 02, 2023 12:17 PM Eastern Daylight Time

Video

News Release

Willow Bioscience agrees to partnership with biotech company looking at age-related diseases

Willow Biosciences Inc.

Willow Bioscience CEO Dr Chris Savile joined Steve Darling from Proactive to share news the company has agreed to a Master Services Agreement with an innovative biotech company with the focus on age-related diseases. This partnership will see the company develop precision fermentation processes for a class of molecules to develop novel solutions for age-related diseases. Savile also told Proactive about another key partnership with Kalsec Inc to develop an enzyme used in production of a new, advanced ingredient used in natural beverage applications. This is the second collaborative development program the two parties will be working on. The goal is to commercialize these products quickly and effectively, leveraging partnerships for market access while retaining the option to bring proprietary ingredients to market independently. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

June 02, 2023 11:51 AM Eastern Daylight Time

Video

MGC Pharmaceuticals to "keep chipping away" after first CannEpil delivery

MGC Pharmaceuticals Ltd

Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

June 02, 2023 10:17 AM Eastern Daylight Time

Video

Revolutionize Preclinical Drug Candidate Discovery with Syntekabio

Syntekabio, Inc.

Syntekabio (KOSDAQ: 226330), an artificial intelligence (AI) drug discovery and development company headquartered in South Korea, announced today the launch of its cost-effective AI-based total solution service for finding new drug candidates. STB CLOUD works as a comprehensive one-stop solution built on Syntekabio's own proprietary AI platform DeepMatcher®, powered by supercomputing technology. The total solution supports auto-hit-discovery, auto-lead-generation, auto-ADMET/PK (at task), and PGx biomarker for drug labeling. Using deep-learning analysis and automatic molecular dynamics (MD) simulation technology for target proteins, the solution generates pre-stage, pre-clinical candidates within two years, including the completion of animal testing. This process drastically shortens the period before pre-clinical trials to two years from what averages to be up to seven years in traditional drug development. Generally, it takes three to four years for candidate discovery and screening, one to three years for optimization, and the same length for non-clinical and toxicity tests. Adding five to six years for clinical trials and a couple more years for commercialization, the time it takes for full drug development from discovery can last many years causing the development price tag to go up while losing potential return on investment. Furthermore, Traditional new drug development can cost more than 10 million dollars until pre-clinical trials. Syntekabio’s STB CLOUD not only saves time but achieves substantial cost savings as it is set at only two million dollars for the entire cycle of drug development. “Using our AI-based STB CLOUD and supercomputing technology, we have created an optimal environment for servicing the global biopharma industry,” CEO of Syntekabio, Jongsun Jung, said. “The fully automated technology covers toxicity, metabolism and pharmacokinetics prediction and will provide in the near future an automated total service for each individual model. It’s only a matter of time to automatically produce drugs with high unmet needs, including rare disease treatments.” Currently, Syntekabio is conducting two studies in the area of auto-ADMET/PK (at task). The first is about toxicity and metabolism caused by protein binding, which is modeled based on the 3D convolutional neural network (3D-CNN). The second study is on passive delivery and permeability due to the physical and chemical properties of the compound itself, which will be implemented with pre-trained generative transformers models, such as GPT-2, using large-scale compound databases. Syntekabio’s new drug discovery solutions will be unveiled at the 2023 BIO International Convention in Boston, June 5-8 at booth #2785. Contact Ellie Woo at ellie.woo@syntekabio.com or +1 (917) 257-4533 to request one-on-one meeting. ### About Syntekabio Syntekabio is a global artificial intelligence (AI) and big data-based drug discovery and development company, headquartered in South Korea since 2009, with U.S. operations bringing innovative technologies and science to create transformative medicines worldwide that are compliant with international standards to cure diseases and improve people's lives. Find out more about DeepMatcher®, NEO-ARS™, NGS-ARS™ and PGM-ARS™ at STB CLOUD (syntekabio.com) Media Contact Syntekabio USA Email: admin.usa@syntekabio.com Tel: +1 212-371-2544 Contact Details Syntekabio inc. Ellie Woo +1 212-371-2544 admin.usa@syntekabio.com Company Website https://cloud.syntekabio.com/main

June 01, 2023 05:00 PM Eastern Daylight Time

Cohen Institute Mental Health Conference in Evanston to Focus on Managing Stress

The Chicago School of Professional Psychology

The Naomi Ruth Cohen Institute for Mental Health Education (NRCI) at The Chicago School of Professional Psychology (TCSPP) will bring together the community and professionals on June 10, 2023 to discuss "Untying the Human Knot: Managing Stress & Anxiety in Today's World." The conference is set for 9:30am-3:30pm at Evanston Township High School (1600 Dodge Ave., Evanston, Ill., 60201). Registration is available at the door. The 90-minute opening panel presentation features Gabriela Diaz, Orson Morrison, PhD, and Paula R. Young, PhD, ACT. The panel will be moderated by Michael Horowitz, PhD, President of The Community Solution Education System. The panel will be followed by three rounds of professional-led breakout sessions as well as a post-event networking session. Lunch is included. Gabriela Diaz is a Chicago-based actor, teaching artist, and mental health advocate. She received her BFA at Webster University’s Leigh Gerdine College of Fine Arts. She has worked with The Art Institute, Steppenwolf Theatre, Firebrand Theatre, Jackalope Theatre, and others. Gabriela has found a creative home at Erasing The Distance (ETD), where she combines her passion for the arts and mental health. As a person living with anxiety, Gabriela finds immense joy in sharing her story to spark dialogue about the human experience. Orson Morrison, PhD, is a licensed clinical psychologist and the co-owner of LifeSpan Counseling and Psychological Services. He is also the Associate Director of Clinical Services for DePaul University Counseling & Psychological Services. He has worked in a variety of clinical settings including college counseling centers, community mental health centers, medical settings, private practice, and in academic-clinical research units. His professional interests and areas of expertise include psychotherapy with children, adolescents, adults, and families; racial and intergenerational trauma; psychological assessment; and contemplative practices. Paula R. Young, PhD, ACT, is a licensed clinical psychologist and senior clinical director at Rogers Behavioral Health. There, she leads the clinicians who are focused on adolescent and adult mental health. Dr. Young, who received her doctorate from Finch University of Health Sciences/The Chicago Medical School, has extensive experience working with those with depression and anxiety disorders. She has presented to numerous clinical and academic audiences across the country. Michael Horowitz, PhD, is the President of The Community Solution Education System. Dr. Horowitz leads The Community Solution and its system of nonprofit colleges and universities including The Chicago School of Professional Psychology (TCSPP). Dr. Horowitz received his Ph.D. in Clinical Psychology from Northwestern University in 1986. The professional-led breakout sessions include informative presentations on topics like managing stress and anxiety at different stages of one’s life, building resilience, developing healthy coping mechanisms, and other topics. The conference is open to all community members and offers CEUs to licensed mental health and other professionals. Tickets will be available for $45 (with an added $25 for those seeking CEUs). Partial and full scholarships are available. Since 2002, NRCI has hosted an annual community mental health conference in Evanston, Ill., to bring together those with lived experience, their caregivers, supporters, and treatment professionals as well as members of the community interested in learning more about a specific mental health challenge or issue. NRCI is committed to providing mental health education and training in the Chicagoland area, and reducing the stigma often associated with mental health challenges and suicide, a cause the organization’s founders, Larry and Marilyn Cohen, embraced after their daughter Naomi died by suicide after living with bipolar disorder. About The Chicago School of Professional Psychology: Integrating theory with hands-on experience, The Chicago School of Professional Psychology provides education rooted in a commitment to innovation, service, and community for thousands of diverse students across the United States and globally. Founded in 1979, the nonprofit, regionally accredited university now features campuses in iconic locations across the country (Chicago, Southern California, Washington, D.C., New Orleans, Dallas) and online. To spark positive change in the world where it matters most, The Chicago School has continued to expand its educational offerings beyond the field of psychology to offer more than 30 degrees and certificates in the professional fields of health services, education, counseling, business, and more. Through its engaged professional model of education, commitment to diversity and inclusion, and an extensive network of domestic and international professional partnerships, The Chicago School’s students receive real-world training opportunities that reflect their future careers. The Chicago School is proud to be a part of TCS Education System, a nonprofit, integrated system of colleges and universities that works collaboratively to advance student success and community impact. To learn more, visit www.thechicagoschool.edu. Contact Details Vivien Hao +1 323-893-4743 vhao@thechicagoschool.edu

June 01, 2023 12:00 PM Eastern Daylight Time

Galexxy Holdings Inc., Appoints High Profile Chief Marketing Officer

GALEXXY HLDGS INC.

Galexxy Holdings Inc., (“Galexxy” or “Company”) (OTC: GXXY) is pleased to advise that it has appointed Dan Gay as its Chief Marketing and Sales Officer. Dan has a very successful background as a senior marketing and sales executive, adept at creating new markets, forming strategic sales alliances, and developing rapid growth of sales revenue. Dan’s early background includes senior positions with MCI Telecom (200 employees increased to 30,000 during his tenure), and Qwest, which grew to a $60 billion company. At MCI he managed sales teams in a 15-state region, which led national sales by adding $115m in new revenues. He became one of the highest-producing regions in the U.S. Dan also created and managed a 450-employee outreach Call Center, increasing MCI’s client base by 420,000 customers. At Qwest, Dan transformed an underperforming division to surpass plan and was chosen for the executive team that acquired and integrated the $44 billion US West telephone company. Dan was appointed Vice President and Chief Marketing Officer (CMO) of iThrive Health (2010-2017) a consortium targeting physicians and consumers with proprietary software offering 10,000-plus health products. Dan increased online revenues by 315%, grew the client base by 500%, and expanded SKUs six-fold. He also negotiated joint partnerships and led the successful acquisition of a related products company. More recently, in 2018 Dan was appointed Chief Marketing and Sales Officer of a leading blockchain growth company with employees and partner channels on 6 continents. As a member of the senior executive team, he tripled sales growth in 2022, brought 9 new products to market with thousands of daily downloads, and negotiated millions in angel investments. Galexxy’s CEO, Michael Biagi stated that; “Dan has the motivation and innovative expertise to build important strategic partnerships and drive our revenue growth to enable us to up-list onto NASDAQ”. Galexxy is headquartered in Newport Beach and its shares are publicly traded on the OTC Markets (OTC: GXXY). Galexxy entered the rapidly developing markets for premium natural plant-based health supplements and superfoods in April 2021, and completed its acquisition of Wellbeing Farms LLC., on August 4, 2022, and purchased 69% of ABC Wholesale Products LLC., on August 12, 2022. Galexxy Holdings Inc. CEO Michael Biagi E: Michael@galexxyholdings.com M: (801) 243 9570 Forward-Looking Information This press release contains “forward-looking information” and “forward-looking statements” (collectively, “statements”). All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this press release. www.galexxyholdings.com www.wellbeingfarms.com https://twitter.com/GXXYHoldings Contact Details Galexxy Holdings Inc. Michael@galexxyholdings.com

June 01, 2023 10:00 AM Eastern Daylight Time

1 ... 116 117 118 119 120 ... 301